

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

***End of offering period of the share capital increase, 99.24%
subscribed for a total amount of Euro 49.4 million***

Unexercised option rights will be offered on the Milan Stock Exchange from 1st April 2015

Milan, 30 March 2015 – MolMed S.p.A. (“**MolMed**” or the “**Issuer**”) announces that the rights offering of No. 187,311,408 newly issued MolMed ordinary shares (the “**Shares**”) has been completed today.

During the offering period, which started on 9 March 2015 and ended on 30 March included, (the “**Offering Period**”), No. 184,693,240 rights were exercised for the subscription of No. 147,754,592 Shares, equal to 99.24% of the total offered Shares, for a total amount equal to Euro 39,302,721.48 net of the amount of Euro 10,144,774.00 anticipated as an advance payment on future share capital increase by shareholders Fininvest S.p.A., Airain Ltd., H-Equity S.r.l. and H-Invest S.p.A. In particular, Fininvest, Airain, H-Equity and H-Invest have subscribed the share capital increase under the terms and conditions already disclosed to the market.

The Chairman and CEO, Professor Claudio Bordignon commented: *“We are extremely pleased by this important result which confirms our shareholders’ trust and acknowledges progress made by our Company, as well as the significance of MolMed’s strategic choices and therapies. The success of this operation will allow us to complete the development of our most advanced products and enrich our pipeline, consolidating our leadership in the field of immunogene therapy of cancer.”*

The No. 1,773,220 option rights that were not exercised during the Offering Period (the “**Unexercised Rights**”), related to the subscription of No. 1,418,576 new shares, corresponding to 0.76% of the total Shares, for a total amount equal to Euro 377,341.22 will be offered on the Milan Stock Exchange pursuant to Article 2441, third paragraph of the Italian Civil Code, by Banca IMI S.p.A. during the trading sessions of 1, 2, 7, 8 and 9 April 2015, except in case of early closing (the “**Offer to the Market**”). All Unexercised Rights will be offered during the first trading session; any residual Unexercised Rights will be offered in the following trading sessions.

The Unexercised Rights may be used to subscribe the Shares - having the same characteristics of the outstanding MolMed ordinary shares as of the relevant issuance date and with regular entitlement – at a price of Euro 0.2660 per share (of which Euro 0.0471 attributed to share capital and the remaining amount to share premium) based on a ratio of no. 4 Shares for every No. 5 Unexercised Rights.

The exercise of the Unexercised Rights purchased during the Offer to the Market and, therefore, the subscription of the relevant Shares, shall be carried out exclusively through authorised intermediaries members of the centralised management system of Monte Titoli S.p.A. under penalty of forfeiture, by and no later than 10 April 2015, with the same value date, except in the event of early closing of the Offer to the Market, following the sale of all the Unexercised Rights offered during the first or the second trading session.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

Settlement date in the event of early closing of the Offer to the Market

In case of early closing of Offer to the Market, the Unexercised Rights purchased under the abovementioned offering must be exercised in advance, under penalty of forfeiture, by and no later than the third trading day following the early closing notification, and therefore:

- by and no later than 8 April 2015, with the same value, in the event of early closure on 1 April 2015;
- by and no later than 9 April 2015, with the same value, in the event of early closure on 2 April 2015.

In any case, it is understood that if the Unexercised Rights being offered are not all sold during the first two trading days mentioned above (i.e. at the sessions on 1 and 2 April 2015), the deadline for subscription of the Shares will still fall on 10 April 2015.

The Shares obtained by exercising the Unexercised Rights will be deposited on the accounts held by the authorised intermediaries members of the centralised management system of Monte Titoli S.p.A. at the end of the accounting date of the last Unexercised Rights exercise day and will therefore be made available on the following settlement day.

The Registration Document, the Information Note and the Summary Note, as well as the Supplement, are available to the public at the registered office of MolMed, in Milan (Italy), via Olgettina, n. 58 and on MolMed's website (www.molmed.com).

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This communication does not constitute an offer or an invitation to subscribe for or purchase any Securities. The securities referred to herein have not been registered and will not be registered in the United States under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or in Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would require the approval of local authorities or otherwise be unlawful. The securities may not be offered or sold in the United States or to U.S. persons unless such securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the



PRESS RELEASE

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

**General Manager Corporate Governance & Administration
Investor Relations Director *ad int.***

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.